Atopic Dermatitis

A 200 mg single-dose prefilled pen for Dupixent has been approved by the FDA for at-home use to treat certain patients with atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis, according to a company announcement.

Both a 4 mg and 2 mg dosing regimen of oral baricitinib yielded positive outcomes in patients with moderate to severe atopic dermatitis, according to a study.

Patients with atopic dermatitis who were treated with internet-delivered cognitive behavioral therapy had a significant reduction in symptoms, according to a study.

Upadacitinib, an oral JAK inhibitor, was effective in treating moderate to severe atopic dermatitis in two phase 3 clinical trials.

A childhood diagnosis of atopic dermatitis was associated with lower attainment of secondary education but not higher education, according to a population-based study.

In this video, Michael J. Cork, BSC, MB, PhD, FRCP, discusses how data from posters being presented at AAD VMX 2021 on dupilumab reinforce his experience of how life-changing dupilumab treatment can be in children with atopic dermatitis.

In this video from AAD VMX 2021, Andrew Blauvelt, MD, MBA, discusses his presentation on the necessity of laboratory testing for adult patients on long-term dupilumab treatment for moderate to severe atopic dermatitis.

Etrasimod, an investigational drug for moderate to severe atopic dermatitis, demonstrated statistically significant improvements in a phase 2b clinical trial, according to a study presented at AAD VMX 2021.

Long-term use of tralokinumab is safe and efficacious in the treatment of atopic dermatitis, according to a presentation at AAD VMX 2021.

Atopic dermatitis severity is associated with learning disabilities in children, according to a study.